In this study, we aimed to determine the clinical implications of Romo1 expression in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma treated with first-line tyrosine kinase inhibitors (TKIs). This evidence concerns the gene ROMO1 and lung adenocarcinoma.